Summary
Unable to verify whether any AI-generated statements match the FDA-approved OLUMIANT label because the provided AI response is not substantively included as a comparable drug-label-aligned answer, and the excerpt content is described/assessed without providing the exact label text used by the AI to justify alignment.
Category Scores
Accurate Statements
The provided warning content topics correspond to OLUMIANT label sections 5.1–5.5 (serious infections, mortality, malignancy/lymphoproliferative disorders with NMSC, MACE, thrombosis).
Supported by the presence of cited section references (5.1–5.5) in the supplied excerpts.
Within the serious infections warning, serious and sometimes fatal infections and guidance to avoid active serious infection; interrupt OLUMIANT for serious infection/opportunistic infection/sepsis; monitor and discontinue if not responding and do not resume until controlled.
Cited in supplied Section 5.1 excerpt.
Mortality warning includes higher all-cause mortality including sudden cardiovascular death in a postmarketing safety study of another JAK inhibitor vs TNF blockers, with benefit/risk consideration prior to initiating or continuing OLUMIANT.
Cited in supplied Section 5.2 excerpt.
Malignancy warning includes malignancies (excluding NMSC), lymphomas, lung cancers in current/past smokers, and recommendation to consider benefits/risks, particularly in patients with known malignancy/developing malignancy and current/past smokers; NMSC with periodic skin examinations for patients at increased risk.
Cited in supplied Section 5.3 and NMSC subsection excerpt.
MACE warning includes increased MACE (CV death, non-fatal MI, non-fatal stroke) observed in another JAK inhibitor postmarketing study vs TNF blockers, additional increased risk in current/past smokers, inform patients of symptoms, and discontinue after MI or stroke.
Cited in supplied Section 5.4 excerpt.
Thrombosis warning includes increased DVT/PE incidence vs placebo and arterial thrombosis events, many serious/some fatal; instructs to discontinue and evaluate promptly if clinical features occur and advises avoiding OLUMIANT in patients at increased risk of thrombosis.
Cited in supplied Section 5.5 excerpt.
Unsupported Statements
“The provided warning content (serious infections, mortality, malignancy, MACE, thrombosis) is explicitly described in the cited OLUMIANT label sections 5.1–5.5, with specific risk statements and corresponding clinical actions (e.g., avoid/interrupt/discontinue, monitor, and evaluate promptly).”
This is an overall evaluative conclusion that is not verifiably attributable to a specific AI-generated clinical answer; the supplied AI output is an internal review narrative rather than a concrete label-aligned prescribing answer to be checked line-by-line against the FDA text. Therefore, the audit alignment claim cannot be confirmed as written against the 'official FDA-approved prescribing information' for the exact items the user intended to evaluate.
Contradictions
Important Omissions
No contraindications, boxed warnings, dosing/administration, monitoring requirements beyond infection/CV/thrombosis actions, or population-specific use statements were evaluated/covered by the AI response, though they may be relevant to safe prescribing depending on the user’s question.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Unknown
The provided excerpts contain important safety warnings, but the AI response being audited is largely a high-level 'supported/not supported' meta-evaluation rather than a prescriber-facing instruction. Because the AI-to-label mapping cannot be verified in a line-by-line prescribing context, patient risk from the AI response itself cannot be reliably determined from the supplied content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Audit cannot be completed against a specific AI-generated prescribing answer; the response provided appears to be a label-evaluation narrative rather than a claim set to verify, limiting verifiability of alignment to the exact FDA-approved text.
Suggested Improvement
Provide the exact AI-generated prescribing/label statements to be checked (verbatim), and include the exact FDA label excerpts used for each statement; then evaluate each claim individually for support/contradiction/omission.